Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting
J Lin, J Trocio, K Gupta, J Mardekian… - Journal of medical …, 2017 - Taylor & Francis
Aims: This study compared the risk for major bleeding (MB) and healthcare economic
outcomes of patients with non-valvular atrial fibrillation (NVAF) after initiating treatment with …
outcomes of patients with non-valvular atrial fibrillation (NVAF) after initiating treatment with …
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed …
A Amin, A Keshishian, L Vo, Q Zhang… - Journal of Medical …, 2018 - Taylor & Francis
Aims: To compare the risk of all-cause hospitalization and hospitalizations due to
stroke/systemic embolism (SE) and major bleeding, as well as associated healthcare costs …
stroke/systemic embolism (SE) and major bleeding, as well as associated healthcare costs …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2018 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the US Department of Defense …
BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants
AM Gilligan, J Franchino-Elder, X Song… - … medical research and …, 2018 - Taylor & Francis
Objectives: Compare costs and healthcare resource utilization (HCRU) among newly-
diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs …
diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs …
Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation
A Amin, M Stokes, N Wu, E Gatt… - Journal of medical …, 2013 - Taylor & Francis
Abstract Objective: The Apixaban for Reduction in Stroke and Other Thromboembolic Events
in Atrial Fibrillation (ARISTOTLE) trial demonstrated that apixaban was effective in reducing …
in Atrial Fibrillation (ARISTOTLE) trial demonstrated that apixaban was effective in reducing …
[HTML][HTML] Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks
S Deitelzweig, A Amin, Y Jing, D Makenbaeva… - Cardiology and …, 2013 - Springer
Abstract Introduction The Apixaban for the Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous …
A Amin, A Bruno, J Trocio, J Lin… - Journal of Medical …, 2015 - Taylor & Francis
Objective: Medical costs that may be avoided when any of the four new oral anticoagulants
(NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, are used instead of warfarin …
(NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, are used instead of warfarin …
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients≥ 75 and< …
S Deitelzweig, A Amin, Y Jing… - Journal of Medical …, 2013 - Taylor & Francis
Objectives: Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran,
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …